Skip to main content
. Author manuscript; available in PMC: 2017 Apr 1.
Published in final edited form as: Am J Clin Oncol. 2016 Apr;39(2):189–195. doi: 10.1097/COC.0000000000000033

Table 2.

Analysis of factors and values as predictors of overall survival (top) and hepatic progression free survival (bottom) in 50 patients with analyzed pre-treatment FDG PET/CT. Metabolic tumor volume (MTVpre) was omitted from multivariate analysis as it is highly correlated with total glycolic activity (TGApre).

Overall survival
Univariate analysis Multivariate analysis
Parameter Hazard
ratio (HR)		 p HR per
100 units		 Parameter Hazard
ratio (HR)		 p HR per
100 units
Age 1.0011 0.9206 - Age - - -
Female 0.374 0.0123 - Female 0.3373 0.0007 -
KPS* 0.9642 0.0756 - KPS - - -
Extrahepatic Disease 1.333 0.4083 - Extrahepatic Disease - - -
SUVmax, pre 1.0483 0.3098 - SUVmax, pre - - -
MTVpre 1.0017 0.0003 1.1888 MTVpre Omit - -
TGApre 1.0006 <0.0001 1.0668 TGApre 1.0007 <0.0001 1.0714
Hepatic progression free survival
Univariate analysis Multivariate analysis
Parameter HR p HR per
100 units 		Parameter HR p HR per
100 units
Age 0.9965 0.7517 - Age - - -
Female 0.4644 0.0267 - Female 0.4492 0.0217 -
KPS 0.9849 0.4875 - KPS - - -
Extrahepatic Disease 1.917 0.0564 - Extrahepatic Disease - - -
SUVmax, pre 1.0352 0.3412 - SUVmax, pre - - -
MTVpre 1.0011 0.0367 1.1142 MTVpre Omit - -
TGApre 1.0004 0.007 1.0443 TGApre 1.0005 0.0055 1.0469
*

Abbreviations: KPS=Karnofsky performance status, SUVmax=standard uptake value, MTV=metabolic tumor volume, TGA=total glycolic activity